questionText: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 30 November 2023 to Question 3472 on Cystic Fibrosis: Drugs, when she expects the National Institute for Health and Care Excellence to publish their final guidance on the 
answerText: The National Institute for Health and Care Excellence (NICE) published draft guidance on 3 November 2023 which does not recommend Orkambi (lumacaftor-ivacaftor), Symkevi (ivacaftor-tezacaftor) and Kaftrio (ivacaftor–tezacaftor–elexacaftor) for the treatme...
heading: Ivacaftor/tezacaftor/elexacaftor